Latest News 2021 2020 2019 2018 2017 2016 2015 2014 November 02 Wellinks Announces $25M in New Funding to Expand First Integrated Virtual COPD Management Solution to More Patients October 26 Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting October 25 Aziyo Biologics Provides Business Update and Preliminary Third Quarter 2021 Revenue Results and Announces Timing for Third Quarter 2021 Financial Results October 19 Quantum-Si Announces Expansion of Early Access Program for the Platinum™ Single Molecule Protein Sequencing Platform August 31 Aziyo Biologics Appoints Peter G. Edwards as General Counsel August 16 Quantum-Si Reports Second Quarter 2021 Financial Results August 09 Aziyo Biologics Reports Second Quarter 2021 Financial Results July 23 Quantum-Si Signs Lease for Product Development and Operations Facility in San Diego Biotechnology Hub June 10 Quantum-Si, Revolutionizing Proteomics, Closes Business Combination and Will Begin Trading Under the Ticker “QSI” on the Nasdaq Stock Exchange June 08 Cybrexa Therapeutics Announces Publication of Peer-Reviewed Article in NAR Cancer June 02 HighCape Capital Acquisition Corp. Reminds Stockholders to Vote in Favor of the Business Combination with Quantum-Si Incorporated May 20 Cybrexa Therapeutics Appoints Stephen Basso as Chief Financial Officer May 17 Quantum-Si and HighCape Capital Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination May 10 Cybrexa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of CBX-12 (alphalex™-exatecan) in Advanced or Metastatic Refractory Solid Tumors April 29 Quantum-Si Appoints Dr. Michael Mina as Chief Medical Advisor April 22 Quantum-Si Announces Appointment of Claudia Napal Drayton as Chief Financial Officer March 23 Cybrexa Therapeutics Receives Green Light from FDA on Investigational New Drug Application for CBX-12 (alphalex™-exatecan) March 10 Cybrexa Therapeutics Closes $25 Million Series B Financing March 08 Cybrexa Therapeutics Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop CBX-12 (alphalex™- exatecan) March 01 Aziyo Biologics Reports Fourth Quarter and Full Year 2020 Financial Results February 18 CNBC Interview: Inventor Dr. Rothberg on Quantum-Si SPAC deal February 18 Quantum-Si, a Pioneer in Semiconductor Chip-Based Proteomics, to Combine with HighCape Capital Acquisition Corp. February 17 Aziyo Biologics Announces First Patient Enrolled in HEAL Study January 28 Cybrexa Therapeutics Reports Positive Results from GLP Toxicology Study of Lead Candidate CBX-12 (alphalex™-exatecan) January 28 Aziyo Biologics Announces Updated CanGaroo® Envelope Label in European Markets to Allow for Hydration in an Antibiotic Solution January 25 21 New “Kids” on the Block: The Most Recent Entrants into the Greater New Haven Biotech Hub January 14 Wellinks Announces Initiation of IRB Approved Study of Digital Health Solution for COPD January 12 Surgalign Holdings Announce the Commercial Launch of ViBone® Moldable and the First Clinical Implantation December 15 Athena Therapeutics announces initial financing from Highcape Capital and Connecticut Innovations November 19 Aziyo Biologics Reports Third Quarter 2020 Financial Results November 17 Aziyo Biologics to Participate in the Piper 32nd Annual Virtual Healthcare Conference November 16 Surgalign Holdings and Aziyo Biologics Announce Expanded Distribution Agreement November 12 Aziyo Biologics Awarded Breakthrough Technology Contract with Premier Inc. November 05 Aziyo Biologics to Report Third Quarter 2020 Financial Results on Thursday, November 19, 2020 October 23 HighCape Capital Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about October 26, 2020 October 07 Aziyo Biologics Announces Pricing of Initial Public Offering September 28 Aziyo Biologics Announces Appointment of Chief Financial Officer September 21 Aziyo Biologics Announces New Appointments to Board of Directors September 09 HighCape Capital Acquisition Corp. Announces Closing of $115 Million Initial Public Offering September 03 HighCape Capital Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering July 23 Wellinks has been awarded 2020 Venture of the Year from the CT Entrepreneur Awards July 09 TELA Bio Announces Interim Analysis from BRAVO Study of OviTex® for Ventral Hernia Repair June 30 TELA Bio Announces Closing of Public Offering of Common Stock June 29 Aziyo Biologics Announces Launch of OsteGro® V June 25 TELA Bio Announces Pricing of Public Offering of Common Stock June 23 TELA Bio Announces Proposed Public Offering of Common Stock June 15 TELA Bio, Inc. Announces Poster Presentations at the 2020 Minimally Invasive Surgery Symposium (MISS) April 23 TELA Bio Announces Changes to its Board of Directors January 08 Convexity Scientific Wellinks Announcement Convexity Activity
